Table 2.
Baseline Characteristics of TyG Index Quartile Groups
| Variables | Q1 (n=216) | Q2 (n=215) | Q3 (n=212) | Q4 (n=215) | P |
|---|---|---|---|---|---|
| ≤8.70 | 8.70–9.20 | 9.20–9.67 | ≥9.67 | ||
| Age, years | 69(60,77) | 69(61,75) | 68.5(59,76) | 69(60,74.5) | 0.908 |
| Male, n% | 126(58.3%) | 117(54.4%) | 126(59.4%) | 109(50.7%) | 0.248 |
| Duration of diabetes, years | 6.5(2,10) | 8(5,10) | 7(3,10) | 8(5,12) | <0.001 |
| BMI, kg/m2 | 22.30(21.30,24.19) | 22.62(21.36,24.99) | 24.85(23.62,26.58) | 25.69(24.51,27.25) | <0.001 |
| WBC,109/L | 6.40(5.20,8.20) | 6.30(5.30,7.65) | 6.50(5.40,8.00) | 7.10(5.55,9.30) | <0.001 |
| RBC,1012/L | 4.11(3.64,4.64) | 4.23(3.8,4.58) | 4.25(3.73,4.71) | 4.27(3.89,4.63) | 0.307 |
| Neutrophils,109/L | 4.30(3.10,5.88) | 3.90(3.00,5.20) | 4.20(3.30,5.58) | 4.60(3.30,6.50) | 0.007 |
| ALT, U/L | 17.00(12.00,27.60) | 16.00(11.60,25.40) | 17.00(12.00,27.50) | 18.50(13.00,29.90) | 0.152 |
| AST, U/L | 19.60(15.63,28.00) | 17.10(13.30,23.00) | 19.00(15.00,24.48) | 19.1(15.00,27.70) | 0.005 |
| Albumin, g/L | 39.30(36.55,42.15) | 39.80(37.20,42.35) | 40.85(36.80,43.25) | 40.00(37.00,43.60) | 0.23 |
| SCr,μmol/L | 73.20(61.50,101.65) | 70.70(58.25,86.7) | 76.35(60.95,106.2) | 71(59.4,102.95) | 0.082 |
| BUN, mmol/L | 6.37(5.00,8.81) | 5.79(4.79,7.28) | 6.2(4.86,8.36) | 6.4(5.04,8.67) | 0.021 |
| FPG, mmol/L | 6.225(5.08,7.33) | 7.32(6.21,9.08) | 8.495(7.44,9.93) | 10.24(8.62,13.04) | <0.001 |
| TG mmol/L | 0.855(0.68,1.05) | 1.3(1.12,1.54) | 1.86(1.58,2.11) | 2.83(2.18,3.78) | <0.001 |
| TC, mmol/L | 4.03(3.35,4.8) | 4.42(3.57,5.14) | 4.695(3.75,5.4) | 4.9(4.16,5.69) | <0.001 |
| HDL-C, mmol/L | 2.32(1.63,2.85) | 2.56(1.94,3.07) | 2.655(2.05,3.265) | 2.67(2.02,3.32) | <0.001 |
| INR | 1.02(0.92,1.15) | 0.98(0.91,1.08) | 0.995(0.925,1.15) | 0.97(0.91,1.11) | 0.075 |
| Hypertension, n% | 136(63.0%) | 126(58.6%) | 140(66.0%) | 150(69.8%) | 0.098 |
| Medication history | |||||
| ACEI/ARB, n% | 104(48.1%) | 107(49.8%) | 105(49.5%) | 113(52.6%) | 0.83 |
| Statins, n% | 169(78.2%) | 161(74.9%) | 151(71.2%) | 171(79.5%) | 0.22 |
| Metformin, n% | 37(17.1%) | 42(19.5%) | 53(25%) | 62(28.8%) | 0.016 |
| Alpha-glucosidase inhibitor, n% | 44(20.4%) | 43(20.0%) | 54(25.5%) | 60(27.9%) | 0.143 |
| Sulfonylurea, n% | 48(22.2%) | 38(17.7%) | 36(17.0%) | 30(14.0%) | 0.159 |
| Dipeptidyl peptidase 4 inhibitor, n% | 14(6.5%) | 10(4.7%) | 7(3.3%) | 6(2.8%) | 0.235 |
| Insulin, n% | 41(19%) | 50(23.3%) | 57(26.9%) | 74(34.4%) | 0.002 |
| Aortic calcification, n% | 74(8.6%) | 107(2.5%) | 122(14.2%) | 145(16.9%) | <0.001 |
| Macrovascular complications, n% | 86(39.8%) | 98(45.6%) | 145(68.4%) | 171(79.5%) | <0.001 |
Note: Data are presented as median (IQR) [25th percentile, 75th percentile] or n (%).
Abbreviations: BMI, body mass index; WBC, white blood cell count; RBC, red blood cell count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, blood creatinine; BUN, blood urea nitrogen; FPG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; INR, International normalized ratio; TyG Index, triglyceride glucose index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-converting enzyme inhibitors.